Hematología y Hemoterapia

Resultados: 408
Tipo Título / Nombre Autor(es) Año
Evaluación del ISTH-BAT en los trastornos plaquetarios congénitos: correlación clínica, laboratorio y molecular Bastida JM, Lozano ML, Vaquero M, Tomás-Menor L, Sevivas T, Rodríguez-Alén A, et al 2019
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients Ribera JM, García O, Cervera M, Rguez C, Sirvent M, Vall-Llovera F, et al 2019
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang QZ, Jurczak W, et al 2019
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large b cell lymphoma. Preliminary results of the R2-GDP-GOTEL trial Cruz Merino L de la, Martín García Sancho A, Nogales Fernández E, Carnicero González F, Ríos Herranz E, Cruz Vicente F de la, et al 2019
Mastocitosis Cáceres Hernández S 2019
Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial Ayal RM, Rapado I, Martínez-Cuadron D, Onecha E, Rufian L, Juarez A, et al 2019
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodríguez-Santiago B, Casado JA, et al 2019
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, et al 2019
Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, et al 2019
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study Lozano ML, Mingot-Castellano ME, Perera M, Jarque I, Campos RM, González-López TJ, et al 2019